Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Epilepsy

    Current Location

    Search
    Epilepsy
    Show Map
    Map View
    Your Location
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      78 Epilepsy Trials Near You

      Power is an online platform that helps thousands of Epilepsy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      BHV-7000 for Epilepsy

      Columbus, Ohio
      The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Status Epilepticus, Cluster Seizures, Others
      Must Be Taking:Anti-seizure Medications

      390 Participants Needed

      Cenobamate for Seizures

      Columbus, Ohio
      This trial tests cenobamate, a new medication for controlling seizures, in adults and adolescents with a specific type of epilepsy. The medication is taken regularly to stabilize brain activity and reduce seizures. Cenobamate has shown high effectiveness in previous studies.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Lennox-Gastaut, Drug Abuse, Others
      Must Be Taking:Anti-epileptic Drugs

      169 Participants Needed

      BHV-7000 for Epilepsy

      Columbus, Ohio
      A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Ongoing Adverse Events, Others

      660 Participants Needed

      DBS Therapy for Epilepsy

      Columbus, Ohio
      The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Generalized Epilepsy, Psychogenic Seizures, Others
      Must Be Taking:Antiepileptic Drugs

      140 Participants Needed

      Gene Therapy for Epilepsy

      Columbus, Ohio
      This trial is testing a new treatment called AMT-260 for adults with a type of epilepsy that doesn't respond to usual treatments. The treatment is delivered directly to the affected part of the brain using MRI guidance. The goal is to see if this method can better control seizures and improve safety and tolerability.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Psychogenic Seizures, Contralateral Seizures, Others
      Must Be Taking:Anti Seizure Drugs

      12 Participants Needed

      Focused Ultrasound Thalamotomy for Epilepsy and Anxiety

      Columbus, Ohio
      The purpose of this study is to evaluate the feasibility, safety, and effects on anxiety of high intensity focused ultrasound ablation (FUSA) in patients suffering from treatment-refractory focal epilepsy and anxiety. FUSA is a non-invasive neurosurgical procedure that uses ultrasound waves, sent directly through the scalp and skull, to precisely target small abnormal areas of the brain. For this study, the targeted area of the brain is the anterior nucleus of the thalamus. This brain region may cause seizures and may also be involved in anxiety. The study will test if FUSA is safe and tolerated, and if it reduces anxiety and brain response to threat in patients with anxiety receiving the procedure for partial-onset epilepsy that is resistant to medications.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Low Seizure Frequency, Generalized Epilepsy, Others
      Must Not Be Taking:Anticoagulants, Antiplatelets

      10 Participants Needed

      Focused Ultrasound for Epilepsy

      Columbus, Ohio
      The purpose of this study is to assess the safety and feasibility of unilateral focused ultrasound thalamotomy in adults with focal onset epilepsy whose medicines are not working well. The ExAblate (ExAblate) transcranial system is the name of the device that will be used to create and send ultrasound waves through the scalp and skull precisely to a small structure located in the center of the brain. This structure is known as the "Anterior Nucleus", and is an important region in the brain that may cause seizures. Safety will be measured by recording and analyzing the frequency of side effects throughout participation. Feasibility will be measured by the ability to create a lesion in the anterior nucleus.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Low Seizure Frequency, Vagal Nerve Stimulator, Untreated Neuropsychiatric Disorders, Recent Substance Abuse, Others
      Must Be Taking:Anti-epileptic Drugs

      10 Participants Needed

      XEN1101 for Seizures

      Columbus, Ohio
      This trial tests XEN1101, a medication added to current treatments, in people with generalized epilepsy experiencing PGTCS who are already on 1-3 anti-seizure medications. The goal is to see if taking XEN1101 with an evening meal can help reduce seizure frequency.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Focal-onset Seizures, Schizophrenia, Bipolar, Others
      Must Be Taking:Antiseizure Medications

      160 Participants Needed

      Zorevunersen for Dravet Syndrome

      Columbus, Ohio
      The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 17

      Key Eligibility Criteria

      Disqualifiers:SCN1A Gain-of-function, Neuromodulation, Others
      Must Be Taking:Anti-seizure Medications

      150 Participants Needed

      EPX-100 for Dravet Syndrome

      Columbus, Ohio
      The purpose of this study is to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in participants with Dravet syndrome.
      Stay on current meds

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:2 - 80

      Key Eligibility Criteria

      Disqualifiers:Suicidal Thoughts, Cardiac Disease, Others
      Must Be Taking:Aeds

      100 Participants Needed

      XEN1101 for Partial Seizures

      Columbus, Ohio
      The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Generalized Seizures, Psychogenic Seizures, Others
      Must Be Taking:Antiseizure Medications

      360 Participants Needed

      LP352 for Epilepsy

      Columbus, Ohio
      This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:2 - 66

      Key Eligibility Criteria

      Disqualifiers:Neurologic, Psychiatric, Cardiovascular, Others
      Must Be Taking:LP352

      324 Participants Needed

      LP352 for Dravet Syndrome

      Columbus, Ohio
      This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 65

      Key Eligibility Criteria

      Disqualifiers:Infantile Spasms, Neurodegenerative Disorders, Others
      Must Be Taking:Antiseizure Medications

      160 Participants Needed

      LP352 for Epilepsy

      Columbus, Ohio
      This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 65

      Key Eligibility Criteria

      Disqualifiers:Dravet Syndrome, Neurodegenerative Disorders, Others
      Must Be Taking:Antiseizure Medications

      320 Participants Needed

      BHV-7000 for Epilepsy

      Dayton, Ohio
      The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Status Epilepticus, Cluster Seizures, Others
      Must Be Taking:Anti-seizure Medications

      390 Participants Needed

      XEN1101 for Epilepsy

      Dayton, Ohio
      This trial tests XEN1101, a new medication, in adults with focal epilepsy who still have seizures despite taking other anti-epileptic drugs. The goal is to see if XEN1101 can better control their seizures by working with their current medications.
      Stay on current meds

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Psychotic Disorders, Others
      Must Be Taking:AEDs

      325 Participants Needed

      Cannabidiol for Chronic Liver Injury Prevention

      West Chester, Ohio
      This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:1+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Liver Fibrosis, Hepatitis, Others
      Must Be Taking:Epidiolex

      154 Participants Needed

      Cenobamate for Epilepsy

      Cincinnati, Ohio
      Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:2 - 18

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Pseudo-seizures, Psychiatric Disorders, Others
      Must Be Taking:Antiepileptic Drugs

      140 Participants Needed

      Sirolimus for Tuberous Sclerosis

      Cincinnati, Ohio
      This trial is testing sirolimus, a medication that helps control symptoms of Tuberous Sclerosis Complex (TSC), in infants. The goal is to prevent or delay seizures, which can impact long-term brain development. Sirolimus works by turning down the activity of a center in the body that doesn't function properly in TSC. Sirolimus has been studied for its potential to control seizures in pediatric patients with TSC and has shown promising results in improving seizure control.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:1 - 6

      Key Eligibility Criteria

      Disqualifiers:Seizures, Prematurity, Significant Illness, Others
      Must Not Be Taking:Anticonvulsants, MTOR Inhibitors

      64 Participants Needed

      Cenobamate (Xcopri) for Seizures

      Cincinnati, Ohio
      This trial is testing a medication called cenobamate to see how it works in children who have a specific type of seizure. The study will look at how the drug moves through the body and how safe it is when taken over time. Cenobamate aims to calm overactive brain signals that cause these seizures.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:2 - 18

      Key Eligibility Criteria

      Disqualifiers:Progressive Neurological Disease, Hepatic Failure, Renal Failure, Others
      Must Be Taking:Antiepileptic Drugs

      24 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Epilepsy Trial

      Cannabidiol for Seizures

      Cincinnati, Ohio
      This trial tests a medication called GWP42003-P in children under 2 years old who have severe seizure disorders like TSC, LGS, or DS. The study will last over a year and will check if the medication is safe, how it moves through the body, and if it helps reduce seizures. These conditions often don't respond well to usual treatments, so new options are needed. Cannabidiol (pharmaceutical) is approved by the FDA for the treatment of seizures associated with DS, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients ≥1 year of age.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Age:1 - 23

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      27 Participants Needed

      Web-Based Program for Teens with Epilepsy

      Cincinnati, Ohio
      The goal of this multi-site clinical trial is to determine the effectiveness of two components of a web-based intervention (Epilepsy Journey) to improve executive functioning in adolescents with epilepsy. The two components include web-based modules and problem-solving telehealth sessions with a therapist focused on executive functioning. This trial aims to answer the following questions: 1. Which components of Epilepsy Journey (web-based modules or telehealth sessions with a therapist) are essential for improving executive functioning in adolescents with epilepsy? 2. Which components of Epilepsy Journey (web-based modules or telehealth sessions with a therapist) are essential for improving quality of life in adolescents with epilepsy? Participants will be randomly assigned to one of four groups: 1) Epilepsy Journey web-based modules and telehealth sessions, 2) Epilepsy Journey web-based modules only, 3) telehealth sessions with a therapist only, or 4) treatment as usual. Participants will: * Independently review Epilepsy Journey web-based modules focused on executive functioning skills (\~15-30 minutes) and/or have weekly telehealth sessions (\~30-45 minutes) with a therapist for 14 weeks. * Complete measures of executive functioning (parent and teen-report) and quality of life (teen-report) at the start of the study, 14-, 26-, and 66- weeks after randomization. The NIH toolbox will be completed at the start of the study and 26-weeks after randomization. Additional measures will also be collected.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:13 - 17

      Key Eligibility Criteria

      Disqualifiers:Developmental Delay, Severe Mental Illness, Trauma, Others
      Must Not Be Taking:Antiseizure Medications

      310 Participants Needed

      Fenfluramine for CDKL5 Deficiency Disorder

      Cincinnati, Ohio
      This trial tests ZX008, a medication added to current treatments, in children and adults with CDD who have uncontrolled seizures. The goal is to see if ZX008 can help better control their seizures.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:1 - 35

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Cardiovascular Disease, Others
      Must Be Taking:Antiseizure Treatments

      87 Participants Needed

      LY3295668 Erbumine for Neuroblastoma

      Cincinnati, Ohio
      The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:2 - 21

      Key Eligibility Criteria

      Disqualifiers:Transplant, Untreated Brain Tumor, HIV, Others
      Must Not Be Taking:Aurora Kinase Inhibitors

      71 Participants Needed

      Ganaxolone for TSC-Related Epilepsy

      Cincinnati, Ohio
      This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001
      Stay on current meds
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:1 - 65

      Key Eligibility Criteria

      Disqualifiers:Pregnant, CNS Infection, Suicidal, Others

      132 Participants Needed

      Medical Cannabis for Chronic Pain

      Sandusky, Ohio
      This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:7+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Suicidality, Psychosis, Others

      200000 Participants Needed

      XEN1101 for Epilepsy

      Akron, Ohio
      This trial will test the safety and effectiveness of taking a 25 mg pill of XEN1101 in patients with specific types of seizures. The goal is to see if it can help control their seizures by affecting brain activity. Participants must have completed earlier related studies.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Medical Condition, Experimental Device, Others

      880 Participants Needed

      XEN1101 for Seizures

      Akron, Ohio
      The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Non-epileptic Seizures, Generalized Seizures, Others
      Must Be Taking:Antiseizure Medications

      360 Participants Needed

      Vatiquinone Safety for Mitochondrial Disease

      Akron, Ohio
      This trial is testing the safety of vatiquinone, a medication that helps cells produce energy, in people with inherited mitochondrial disease. These participants have already used vatiquinone in previous studies. The study will continue for an extended period. Vatiquinone, also known as EPI-743, is a new oral antioxidant that has been evaluated for mitochondrial diseases.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      102 Participants Needed

      Soticlestat for Dravet Syndrome

      Toledo, Ohio
      This trial tests soticlestat to reduce seizures in children and adults with Dravet Syndrome or Lennox-Gastaut Syndrome. Soticlestat helps by targeting brain pathways involved in seizure activity. The study will evaluate its safety, effectiveness, and tolerance over time.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:2 - 56

      Key Eligibility Criteria

      Disqualifiers:Unstable Neurologic, Psychiatric, Cardiovascular, Others
      Must Be Taking:Anti-seizure Therapy

      400 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Focal Epilepsy Clinical Trials

      20 Depression Trials near High Point, NC

      154 Clinical Trials near Bradenton, FL

      Top Pancreas Cancer Clinical Trials

      Top Hyperhidrosis Clinical Trials

      Top Amblyopia Clinical Trials

      Top Amyloidosis Clinical Trials

      Top Osa Clinical Trials

      Top Cholesterol Clinical Trials

      Top Cardiovascular Clinical Trials

      Top Asd Clinical Trials

      Top Sbrt Clinical Trials

      By Trial

      MRI + iEEG for Epilepsy

      Recorded Music for Epilepsy

      Advanced MRI Techniques for Pediatric Epilepsy

      Mobile Education App for Childhood Epilepsy

      Deep Brain vs Vagus Nerve Stimulation for Epilepsy

      Lifestyle Interventions for Epilepsy

      Brain Monitoring and Stimulation Device for Epilepsy

      Brivaracetam for Absence Epilepsy

      Brain Stimulation for Epilepsy

      Cenobamate for Seizures

      Music Therapy for Epilepsy

      Stimulating Probes and Electrodes for Epilepsy

      Related Searches

      Top Fibromyalgia Clinical Trials near Tampa, FL

      AI-Powered Support for Cancer

      Lung Preservation for Lung Transplant

      Trendelenburg Positioning for Fluid Responsiveness in ICU Patients

      PET Imaging for Melanoma

      SAPIEN 3 THV for Aortic Stenosis

      Continuous Glucose Monitoring for Gestational Diabetes

      Grocery Interventions for Childhood Obesity

      Awareness Interventions for Research Participation

      Diagnostic Tests for Detecting Barrett's Esophagus

      Vaping Prevention Ads for Adolescents and Young Adults

      KRAS Vaccine + Immunotherapy for Lung Cancer

      Frequently Asked Questions

      How much do Epilepsy clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Epilepsy clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Epilepsy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Epilepsy is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Epilepsy medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Epilepsy clinical trials?

      Most recently, we added Ellacor Micro-Coring for Wound Care, Zonisamide for Partial Seizures and Subcortical Arousal Study for Epilepsy to the Power online platform.

      What are the current treatments for epilepsy?

      Treatment usually starts with daily anti-seizure medicines—over 20 are available—and about two-thirds of people become seizure-free after trying one or two of them. If seizures continue, specialists can offer individualized next steps such as surgery to remove the seizure focus, implantable stimulators that “pace” the nerves or brain (VNS, RNS, deep-brain stimulation), dietary therapy like the ketogenic or modified Atkins diet, or newer drugs including purified cannabidiol. The best plan depends on seizure type, age, other health issues and personal preferences, so care is built in partnership with an epilepsy team.

      Are you born with epilepsy or does it develop?

      Epilepsy can start two ways: you might be born with an underlying change in the brain — for example a genetic mutation or a problem that occurred during pregnancy or birth — or you can develop it later after things like a head injury, stroke, tumour or serious brain infection. Roughly one-third of cases are clearly “present from birth,” another third are due to later brain injuries or illnesses, and the rest have no obvious cause yet. In short, some people are born with the tendency, but anyone can develop epilepsy at any age if new damage or disease affects the brain’s electrical circuits.

      What is the rule of 3 for seizures?

      The ILAE’s “Rule of 3” says you can call someone seizure-free when they have gone at least three times as long as their single longest gap between seizures before the new treatment—and in any case at least 12 months—without another event. For example, if the longest break before treatment was 2 months, you need 6 months but because the rule also sets a 12-month minimum you would actually wait a full year; if the longest break was 8 months, you would need 24 months seizure-free. This personalised yard-stick helps doctors judge whether an intervention is truly working and avoids declaring success either too early (for people who naturally had long intervals) or too late (for those who seized frequently).

      What is the most serious epilepsy?

      The most immediately life-threatening situation is status epilepticus—any seizure that lasts five minutes or more or comes back before the person regains awareness; if this happens, give any prescribed rescue medicine and call emergency services because every extra minute increases the risk of brain injury or death. Over the long term, rare drug-resistant childhood syndromes such as Dravet or Lennox-Gastaut are often labeled the “most serious” because they cause daily seizures, developmental problems, and a higher risk of sudden death, so they require care at a specialized epilepsy center and a written emergency plan.

      How likely is epilepsy to go away?

      About two-thirds of children and roughly 60 % of adults who are just starting treatment become seizure-free long-term with medication alone. If seizures continue after trying two suitable drugs, the chance they stop on their own is small (under 5 % per year), but surgery or other specialised treatments can lift the seizure-free rate to about 50-70 % in people who are good candidates. Your exact odds depend on the epilepsy type, brain scans and early response to medicine, so work with your neurologist before deciding whether to stay on, stop, or escalate treatment.

      What foods prevent seizures?

      No single food can guarantee seizure prevention. What has solid evidence is a medically supervised, high-fat/very-low-carb diet (classic ketogenic or its easier cousins, the modified Atkins and low-glycaemic-index plans), which can reduce seizure frequency in about half of patients and make some seizure-free. If you’re not on one of these programs, aim for steady blood-sugar meals—plenty of non-starchy vegetables, healthy fats (olive oil, avocado, nuts, fatty fish), regular protein, and minimal added sugar—and talk with your neurologist or a dietitian before making major changes.

      What do people with epilepsy struggle with?

      People with epilepsy usually face two overlapping hurdles: the seizures themselves—figuring out triggers, preventing injuries, and coping with restrictions on driving, work, or sports—and the wider “after-shocks,” such as memory lapses, mood problems, medication side-effects, stigma, and added financial or school stress. Pinpointing which of these areas is causing the most strain and partnering with a neurologist on medication adherence, mental-health care, safety planning, and community support can greatly reduce risk and help regain independence.

      What is the difference between a seizure and an epilepsy?

      Think of a seizure as a one-time electrical “short-circuit” in the brain that can be set off by things like fever, low blood sugar, or head injury; once the trigger is gone, the risk may disappear. Epilepsy is the medical disorder in which the brain itself has an ongoing tendency to seize—diagnosed when someone has at least two unprovoked seizures (or one unprovoked seizure with a high chance of another), so the focus shifts from treating a single event to managing a long-term condition.

      What is the best epilepsy hospital in the world?

      There is no single “best” epilepsy hospital; what matters is choosing a center that holds the top accreditation for complex epilepsy care (e.g., NAEC Level 4 in the U.S. or an equivalent comprehensive program elsewhere), performs a high number of epilepsy surgeries with good outcomes, and has a multidisciplinary team and active research program. Examples that fit these benchmarks include Mayo Clinic and Cleveland Clinic (USA), King’s College Hospital/UCL in London (UK), University of Bonn (Germany), Pitié-Salpêtrière (France), Toronto Western Hospital (Canada), and Tokyo University Hospital (Japan). Ask your neurologist or local epilepsy foundation which accredited comprehensive center is closest and best suited to your insurance, travel limits, and whether you need adult or pediatric care.

      What is the best exercise for a seizure patient?

      There’s no single “best” exercise for epilepsy—the goal is to choose any activity you enjoy (brisk walking, cycling, swimming with a buddy, light weights, yoga) and do it regularly enough to meet general health targets of ~150 minutes of moderate movement plus two strength sessions weekly. Apply a safety layer: take medications on schedule, avoid personal triggers, wear a medical ID, and have supervision for water or height-related sports; studies and international guidelines show this approach improves fitness, mood, and often reduces seizures without added risk. Always confirm details with your neurologist so the plan fits your seizure pattern and other health factors.